Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the first quarter of 2011, and provided an operating forecast and program updates. “Ligand has had a tremendous start to 2011, highlighted by the acquisition of CyDex Pharmaceuticals in January. CyDex is a transformational deal for Ligand, and we are increasingly excited about this unit’s financial and business potential,” said John Higgins, President and Chief Executive Officer of Ligand Pharmaceuticals. “The Phase I trial of our SARM program is nearing completion with data expected next month, and recent appointments have strengthened our executive management team and board of directors. With several major near-term catalysts anticipated, including pivotal data from two Phase III trials with Promacta® in patients with hepatitis C, 2011 is shaping up to be a momentous year for Ligand.”
